{
    "clinical_study": {
        "@rank": "151289", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose", 
                "arm_group_type": "Active Comparator", 
                "description": "Lactoferrin,dose of 100 mg/day."
            }, 
            {
                "arm_group_label": "High Dose", 
                "arm_group_type": "Experimental", 
                "description": "Lactoferrin, dose of 150 mg/kg/ twice daily."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Receive placebo in form of distilled water."
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis:\n\n      Orally ingested lactoferrin has effects on promotion of growth and differentiation of the\n      immature gut; also it has immunomodulatory properties, so it will prevent serious infections\n      in preterm infants.\n\n      The aim of the study is to:\n\n        -  Evaluate the effectiveness of oral lactoferrin in prevention of neonatal sepsis.\n\n        -  Compare two dose regiment of lactoferrin supplementation.\n\n        -  Study effect of lactoferrin supplementation on serum iron stores.\n\n      It is a prospective, randomized, double blind, placebo-controlled study, it will include 180\n      preterm neonates admitted to the Neonatal Intensive Care Units of of Ain Shams University\n      Hospitals and Manshiet El Bakry Hospital.\n\n      \u2022Group A: Who will receive oral lactoferrin supplementation in a dose of 100 mg/day.\n\n      \u2022Group B: Who will receive oral lactoferrin supplementation in a dose of 150 mg/kg/ twice\n      daily.\n\n      \u2022Group C (Controls): Who match the subjected neonates, will receive placebo in form of\n      distilled water."
        }, 
        "brief_title": "Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate", 
        "condition": "Neonatal Sepsis", 
        "condition_browse": {
            "mesh_term": [
                "Sepsis", 
                "Toxemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Neonates with a birth weight between 500g and 2500g.\n\n          2. Neonates with a \u2264 36 weeks of gestation counting from the first day of the Last\n             Menstrual Period.\n\n          3. Preterm neonates born in, or referred to the Neonatal Intensive Care Units of one of\n             the participating hospitals in the first 48 hours of life.\n\n        Exclusion Criteria:\n\n          1. Neonates with underlying gastrointestinal problems that prevent oral intake.\n\n          2. Neonates with predisposing conditions that profoundly affect growth and development\n             (chromosomal abnormalities, structural brain anomalies, severe congenital\n             abnormalities).\n\n          3. Neonates with a family background of cow milk allergy.\n\n          4. Neonates who will not have the chance to complete the study time (who will be\n             referred to another hospitals).\n\n          5. Neonates whose parents decline to participate.\n\n          6. Neonates with early onset sepsis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "28 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821989", 
            "org_study_id": "moos80"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low Dose", 
                "description": "dose of 100 mg/day", 
                "intervention_name": "Lactoferrin", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "High Dose", 
                "description": "dose of 150 mg/kg/ twice daily", 
                "intervention_name": "Lactoferrin", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "in form of distilled water", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt", 
                    "state": "Abassia"
                }, 
                "name": "Ain Shams University"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate.", 
        "other_outcome": {
            "measure": "C reactive protein quantitative assay", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "overall_contact": {
            "email": "drmooselmokadem@hotmail.com", 
            "last_name": "Mostafa AM Elmokadem, Master", 
            "phone": "01110857100", 
            "phone_ext": "02"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ain Shams university"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Blood culture", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821989"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mooselmokadem", 
            "investigator_full_name": "Mostafa El-Mokadem", 
            "investigator_title": "neonatologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Complete blood count with differential leucocytic count.", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Mooselmokadem", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mooselmokadem", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}